IMMP Key Statistics, Chart & Performance
The current stock price of IMMP is 2.86 USD. In the past month the price decreased by -3.05%. In the past year, price increased by 41.58%.
IMMP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IMMP. When comparing the yearly performance of all stocks, IMMP is one of the better performing stocks in the market, outperforming 93.47% of all stocks.
IMMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMP. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IMMP Financial Highlights
Over the last trailing twelve months IMMP reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -14.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.06% | ||
| ROE | -25.43% | ||
| Debt/Equity | 0 |
IMMP Forecast & Estimates
9 analysts have analysed IMMP and the average price target is 3.3 USD. This implies a price increase of 15.23% is expected in the next year compared to the current price of 2.86.
For the next year, analysts expect an EPS growth of -39.92% and a revenue growth 242.67% for IMMP
IMMP Ownership
IMMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.88 | 398.79B | ||
| AMGN | AMGEN INC | 15.76 | 185.60B | ||
| GILD | GILEAD SCIENCES INC | 17.45 | 177.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.19 | 119.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.01 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 664.92 | 44.80B | ||
| INSM | INSMED INC | N/A | 32.84B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.7 | 26.27B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.45B | ||
| INCY | INCYTE CORP | 15.99 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.45B |
Related stock screener links
About IMMP
Company Profile
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing novel immunotherapies for cancer and autoimmune disease. The company is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Company Info
IMMUTEP LTD-SP ADR
Level 32, Suite 32.07 Australia Square, 264 George Street
Sydney NEW SOUTH WALES 2000 AU
CEO: Marc Voigt
Employees: 0
Phone: 61283157003
IMMUTEP LTD-SP ADR / IMMP FAQ
What does IMMUTEP LTD-SP ADR do?
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing novel immunotherapies for cancer and autoimmune disease. The company is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Can you provide the latest stock price for IMMUTEP LTD-SP ADR?
The current stock price of IMMP is 2.86 USD. The price increased by 4.76% in the last trading session.
Does IMMUTEP LTD-SP ADR pay dividends?
IMMP does not pay a dividend.
What is the ChartMill rating of IMMUTEP LTD-SP ADR stock?
IMMP has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is IMMUTEP LTD-SP ADR (IMMP) expected to grow?
The Revenue of IMMUTEP LTD-SP ADR (IMMP) is expected to grow by 242.67% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for IMMP stock?
IMMUTEP LTD-SP ADR (IMMP) currently has 0 employees.